Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Lumateperone is an atypical antipsychotic.1 It selectively binds to the serotonin (5-HT) receptor subtype 5-HT2A over 5-HT1A and 5-HT2C receptors (Kis = 0.54, 1,480, and 173 nM, respectively). Lumateperone also binds to dopamine D1, D2, and D4 receptors (Kis = 52, 32, and 108 nM, respectively), α1A- and α1B-adrenergic receptors (Kis = 73 and 31 nM, respectively), and the 5-HT transporter (SERT; Ki = 61 nM). It reduces head-twitch behavior induced by the 5-HT2A agonist quipazine in rats (ED50 = 0.12 mg/kg). Formulations containing lumateperone have been used in the treatment of schizophrenia.
WARNING This product is not for human or veterinary use.
1. Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. J. Med. Chem. 57(6), 2670-2682 (2014).